Report cover image

Rabies Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Publisher Global Markets Direct
Published Aug 30, 2022
Length 79 Pages
SKU # GMD17396328

Description

Rabies Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rabies - Drugs In Development, 2022, provides an overview of the Rabies (Infectious Disease) pipeline landscape.
Rabies is a deadly virus spread to people from the saliva of infected animals. The rabies virus is usually transmitted through a bite. Symptoms include loss of feeling in an area of the body, loss of muscle function, swallowing difficult, excitability, fever and convulsions. The predisposing factors include exposure to wildlife and exposure to other pets that may not be vaccinated.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rabies - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Rabies (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Rabies (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Rabies and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 11, 7, 3, 3, 12, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 2, 6 and 2 molecules, respectively.
Rabies (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Rabies (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Rabies (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Rabies (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Rabies (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Rabies (Infectious Disease)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Rabies (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Rabies (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

79 Pages
Introduction
Global Markets Direct Report Coverage
Rabies – Overview
Rabies – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Rabies – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Rabies – Companies Involved in Therapeutics Development
AIM Vaccine Co Ltd
Beijing Minhai Biotechnology Co Ltd
Changchun Bcht Biotechnology Co Ltd
Chengdu Institute of Biological Products Co Ltd
Chengdu Rongsheng Pharmaceutical Co Ltd
China Medical System Holdings Ltd
Chongqing Zhifei Biological Products Co Ltd
Clover Biopharmaceuticals Ltd
CPL Biologicals Pvt Ltd
Curevac NV
Genrix (Shanghai) Biopharmaceutical Co Ltd
Indian Immunologicals Ltd
Jiangsu Kangrun Biological Technology Co Ltd
Liaoning Cheng Da Biotechnology Co Ltd
Mid-Atlantic BioTherapeutics, Inc.
Molecular Targeting Technologies Inc
Oita University Institute of Advanced Medicine Inc
Prosetta Biosciences Inc
Real Benefitspot Pharmaceutical Co Ltd
Sanofi
Shandong Yidu Biotechnology Co Ltd
Shanghai Bovax Biotechnology Co Ltd
Shanghai Qingsai Biotechnology Co Ltd
Shanghai Rongsheng Biotech Co Ltd
Shenzhen Weiguang Biological Products Co Ltd
Synermore Biologics Co Ltd
Trellis Bioscience Inc
Vir Biotechnology Inc
Yisheng Biopharma Co Ltd
Zydus Lifesciences Ltd
Rabies – Drug Profiles
(Lassa fever + rabies) vaccine – Drug Profile
Antibody for Rabies – Drug Profile
B-1014 – Drug Profile
B-1101 – Drug Profile
BNSP-333S1 – Drug Profile
CV-7202 – Drug Profile
GR-1801 – Drug Profile
IMT-504 – Drug Profile
Monoclonal Antibodies for Rabies – Drug Profile
Monoclonal Antibodies to Inhibit Glycoprotein for Rabies – Drug Profile
Monoclonal Antibodies to Target Glycoprotein for Rabies – Drug Profile
New Fully Human Anti-Rabies Virus Antibody Drug (biologic) – Drug Profile
Niprab – Drug Profile
PAV-866 – Drug Profile
rabies immune globulin (human) – Drug Profile
rabies vaccine – Drug Profile
rabies vaccine 1 – Drug Profile
rabies vaccine 2 – Drug Profile
rabies vaccine 3 – Drug Profile
RVC-20 – Drug Profile
RVC-58 – Drug Profile
Small Molecules for Rabies – Drug Profile
SO-57 – Drug Profile
SOJB – Drug Profile
SYN-023 – Drug Profile
VerorabVax – Drug Profile
VRVg-2 – Drug Profile
Rabies – Dormant Projects
Rabies – Discontinued Products
Rabies – Product Development Milestones
Featured News & Press Releases
Jan 24, 2022: Chongqing Zhifei Biological Products Announcement on obtaining the summary report of phase III clinical trial of Lyophilized Human Rabies Vaccine (MRC-5 Cells)
Jan 24, 2022: Kangtai Biology announces registration site verification notice of freeze-dried human rabies vaccine
Jul 16, 2020: Biotec freeze-dried human rabies vaccine (serum-free Vero cells) obtained clinical trial approval
Jun 30, 2020: China develops novel rabies vaccine
Jan 07, 2020: CureVac announces positive results in low dose – 1 µg – Rabies vaccine clinical phase 1 study
Sep 03, 2019: Zydus to launch novel biologic for rabies, Twinrab
Jul 22, 2019: Yisheng Biopharma receives GMP certification from China NMPA for production of lyophilized rabies vaccine for preventive use
Oct 23, 2018: CureVac announces first study participant enrolled in Phase I clinical trial testing prophylactic mRNA
Oct 08, 2018: Yisheng Biopharma announces clearance from China FDA to proceed with PIKA rabies vaccine clinical study
Jun 30, 2017: SYN023, Synermore’s human rabies immunoglobulin antibody drug received IND approval from CFDA for the Clinical Phase I trial study
Jan 04, 2017: US FDA Grants Orphan Drug Designation to Yisheng Biopharma's PIKA Rabies Vaccine
Jan 04, 2016: Yisheng Biopharma Announces Positive Results of Phase I Clinical Trial of a Novel Rabies Vaccine with PIKA Adjuvant
Jul 31, 2015: SYN023, Synermore's human rabies immunoglobulin antibody drug submitted IND application to CFDA for the Clinical Phase I trial study
May 31, 2015: SYN023, Synermore's human rabies immunoglobulin antibody drug received IND approval from FDA for the Clinical Phase I trial study
Apr 30, 2015: SYN023, Synermore's human rabies immunoglobulin antibody drug submitted IND application to FDA for the Clinical Phase I trial study
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Table 1: Number of Products under Development for Rabies, 2022
Table 2: Number of Products under Development by Companies, 2022
Table 3: Number of Products under Development by Companies, 2022 (Contd..1)
Table 4: Number of Products under Development by Universities/Institutes, 2022
Table 5: Products under Development by Companies, 2022
Table 6: Products under Development by Companies, 2022 (Contd..1)
Table 7: Products under Development by Companies, 2022 (Contd..2)
Table 8: Products under Development by Universities/Institutes, 2022
Table 9: Number of Products by Stage and Target, 2022
Table 10: Number of Products by Stage and Mechanism of Action, 2022
Table 11: Number of Products by Stage and Route of Administration, 2022
Table 12: Number of Products by Stage and Molecule Type, 2022
Table 13: Rabies – Pipeline by AIM Vaccine Co Ltd, 2022
Table 14: Rabies – Pipeline by Beijing Minhai Biotechnology Co Ltd, 2022
Table 15: Rabies – Pipeline by Changchun Bcht Biotechnology Co Ltd, 2022
Table 16: Rabies – Pipeline by Chengdu Institute of Biological Products Co Ltd, 2022
Table 17: Rabies – Pipeline by Chengdu Rongsheng Pharmaceutical Co Ltd, 2022
Table 18: Rabies – Pipeline by China Medical System Holdings Ltd, 2022
Table 19: Rabies – Pipeline by Chongqing Zhifei Biological Products Co Ltd, 2022
Table 20: Rabies – Pipeline by Clover Biopharmaceuticals Ltd, 2022
Table 21: Rabies – Pipeline by CPL Biologicals Pvt Ltd, 2022
Table 22: Rabies – Pipeline by Curevac NV, 2022
Table 23: Rabies – Pipeline by Genrix (Shanghai) Biopharmaceutical Co Ltd, 2022
Table 24: Rabies – Pipeline by Indian Immunologicals Ltd, 2022
Table 25: Rabies – Pipeline by Jiangsu Kangrun Biological Technology Co Ltd, 2022
Table 26: Rabies – Pipeline by Liaoning Cheng Da Biotechnology Co Ltd, 2022
Table 27: Rabies – Pipeline by Mid-Atlantic BioTherapeutics, Inc., 2022
Table 28: Rabies – Pipeline by Molecular Targeting Technologies Inc, 2022
Table 29: Rabies – Pipeline by Oita University Institute of Advanced Medicine Inc, 2022
Table 30: Rabies – Pipeline by Prosetta Biosciences Inc, 2022
Table 31: Rabies – Pipeline by Real Benefitspot Pharmaceutical Co Ltd, 2022
Table 32: Rabies – Pipeline by Sanofi, 2022
Table 33: Rabies – Pipeline by Shandong Yidu Biotechnology Co Ltd, 2022
Table 34: Rabies – Pipeline by Shanghai Bovax Biotechnology Co Ltd, 2022
Table 35: Rabies – Pipeline by Shanghai Qingsai Biotechnology Co Ltd, 2022
Table 36: Rabies – Pipeline by Shanghai Rongsheng Biotech Co Ltd, 2022
Table 37: Rabies – Pipeline by Shenzhen Weiguang Biological Products Co Ltd, 2022
Table 38: Rabies – Pipeline by Synermore Biologics Co Ltd, 2022
Table 39: Rabies – Pipeline by Trellis Bioscience Inc, 2022
Table 40: Rabies – Pipeline by Vir Biotechnology Inc, 2022
Table 41: Rabies – Pipeline by Yisheng Biopharma Co Ltd, 2022
Table 42: Rabies – Pipeline by Zydus Lifesciences Ltd, 2022
Table 43: Rabies – Dormant Projects, 2022
Table 44: Rabies – Dormant Projects, 2022 (Contd..1)
Table 45: Table 46: Rabies – Discontinued Products, 2022
List of Figures
Figure 1: Number of Products under Development for Rabies, 2022
Figure 2: Number of Products under Development by Companies, 2022
Figure 3: Number of Products under Development by Universities/Institutes, 2022
Figure 4: Number of Products by Stage and Targets, 2022
Figure 5: Number of Products by Stage and Mechanism of Actions, 2022
Figure 6: Number of Products by Routes of Administration, 2022
Figure 7: Number of Products by Stage and Routes of Administration, 2022
Figure 8: Number of Products by Molecule Types, 2022
Figure 9: Number of Products by Stage and Molecule Types, 2022

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us